Cancer

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Rev. Cancer - 12 February 2019 - 12:00am

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Published online: 12 February 2019; doi:10.1038/s41568-019-0116-x

This Review discusses recent work demonstrating that immune checkpoint inhibitor efficacy is affected by a combination of factors involving tumour genomics, host germline genetics, programmed cell death 1 ligand 1 (PDL1) levels and other features of the tumour microenvironment, as well as the gut microbiome.
Categories: Cancer

Shaping a <i>Nature Reviews Cancer</i> article

Nature Rev. Cancer - 8 February 2019 - 12:00am

Shaping a Nature Reviews Cancer article

Shaping a <i>Nature Reviews Cancer</i> article, Published online: 08 February 2019; doi:10.1038/s41568-019-0120-1

How does a Nature Reviews Cancer Review or Perspectives article move from an idea to a published article? Here, in the spirit of transparency, we provide some insights into this process.
Categories: Cancer

Targeting endovascular progenitors controls cancer

Nature Rev. Cancer - 7 February 2019 - 12:00am

Targeting endovascular progenitors controls cancer

Targeting endovascular progenitors controls cancer, Published online: 07 February 2019; doi:10.1038/s41568-019-0119-7

Targeting endovascular progenitors controls cancer
Categories: Cancer

Epigenetic therapy in immune-oncology

Nature Rev. Cancer - 5 February 2019 - 12:00am

Epigenetic therapy in immune-oncology

Epigenetic therapy in immune-oncology, Published online: 05 February 2019; doi:10.1038/s41568-019-0109-9

In this Review, Jones et al. present the evidence that epigenetic therapies can induce the expression of endogenous retroviruses and cancer–testis antigens normally silenced by DNA methylation in most somatic cells. As a consequence, a state of viral mimicry is evoked in cancer cells, leading to an innate immune response. Understanding this process has implications for combination therapy with epigenetic drugs and immunotherapies to improve clinical outcomes for patients with cancer.
Categories: Cancer

Senolytic helpers

Nature Rev. Cancer - 5 February 2019 - 12:00am

Senolytic helpers

Senolytic helpers, Published online: 05 February 2019; doi:10.1038/s41568-019-0115-y

Ruscetti, Leibold, Bott et al. show that the growth of Kras-mutant lung tumours is sensitive to combined blockade of KRAS effectors. This was dependent on induction of the senescence-activated phenotype in cancer cells, followed by natural killer cell-mediated cell clearance.
Categories: Cancer

Glioblastoma is ‘hot’ for personalized vaccines

Nature Rev. Cancer - 31 January 2019 - 12:00am

Glioblastoma is ‘hot’ for personalized vaccines

Glioblastoma is ‘hot’ for personalized vaccines, Published online: 31 January 2019; doi:10.1038/s41568-019-0118-8

Two phase I studies, recently published in Nature, show that the administration of personalized vaccines to newly diagnosed patients with glioblastoma generates tumour-reactive T cells that infiltrate glioblastomas, turning them into ‘hot’ tumours potentially susceptible to further immunotherapy approaches.
Categories: Cancer

Author Correction: Cancer in wildlife: patterns of emergence

Nature Rev. Cancer - 31 January 2019 - 12:00am

Author Correction: Cancer in wildlife: patterns of emergence

Author Correction: Cancer in wildlife: patterns of emergence, Published online: 31 January 2019; doi:10.1038/s41568-019-0113-0

Author Correction: Cancer in wildlife: patterns of emergence
Categories: Cancer

Unmasking cancer cell character

Nature Rev. Cancer - 31 January 2019 - 12:00am

Unmasking cancer cell character

Unmasking cancer cell character, Published online: 31 January 2019; doi:10.1038/s41568-019-0117-9

Two studies show that cancer cells contain sufficient quantities of immunostimulatory nucleic acids to trigger interferon signalling, increase antitumour immunity and overcome resistance to checkpoint blockade. Loss of the RNA-editing enzyme ADAR1 enables tumour cells to sense these innate ligands.
Categories: Cancer

Methylated clusters

Nature Rev. Cancer - 31 January 2019 - 12:00am

Methylated clusters

Methylated clusters, Published online: 31 January 2019; doi:10.1038/s41568-019-0114-z

Gkountela et al. have identified that circulating tumour cell (CTC) clusters from patients and mouse models with breast cancer have a distinct DNA methylation profile from that of single CTCs, which together with the phenotypic difference represent a targetable therapeutic vulnerability of metastasis.
Categories: Cancer

Author Correction: Every step of the way: integrins in cancer progression and metastasis

Nature Rev. Cancer - 31 January 2019 - 12:00am

Author Correction: Every step of the way: integrins in cancer progression and metastasis

Author Correction: Every step of the way: integrins in cancer progression and metastasis, Published online: 31 January 2019; doi:10.1038/s41568-019-0112-1

Author Correction: Every step of the way: integrins in cancer progression and metastasis
Categories: Cancer

Immune control by amino acid catabolism during tumorigenesis and therapy

Nature Rev. Cancer - 29 January 2019 - 12:00am

Immune control by amino acid catabolism during tumorigenesis and therapy

Immune control by amino acid catabolism during tumorigenesis and therapy, Published online: 29 January 2019; doi:10.1038/s41568-019-0106-z

This Review discusses how increased catabolism of the amino acids tryptophan and arginine driven by inflammatory processes in the tumour microenvironment contributes to tumorigenesis, suppression of antitumour immunity and potentially neurological comorbidities associated with cancer.
Categories: Cancer

Trafficking signals for metastasis

Nature Rev. Cancer - 29 January 2019 - 12:00am

Trafficking signals for metastasis

Trafficking signals for metastasis, Published online: 29 January 2019; doi:10.1038/s41568-019-0111-2

Keklikoglou et al. show that, in mouse models of chemoresistant breast cancer, paclitaxel and doxorubicin trigger the production of tumour-derived extracellular vesicles with pro-metastatic properties that are dependent on annexin A6.
Categories: Cancer

The global cancer burden: necessity is the mother of prevention

Nature Rev. Cancer - 25 January 2019 - 12:00am

The global cancer burden: necessity is the mother of prevention

The global cancer burden: necessity is the mother of prevention, Published online: 25 January 2019; doi:10.1038/s41568-019-0110-3

Cancer brings an increasing health and economic burden worldwide, and the greatest impact is had on the most vulnerable populations. In this Comment, Christopher Wild discusses the need for investment to ensure long-term cancer prevention strategies.
Categories: Cancer

Organoid 2.0

Nature Rev. Cancer - 22 January 2019 - 12:00am

Organoid 2.0

Organoid 2.0, Published online: 22 January 2019; doi:10.1038/s41568-019-0108-x

Neal et al. have successfully established patient-derived organoids of tumour epithelia retaining native immune cells, thereby recapitulating tumour microenvironment diversity and enabling immuno-oncology studies.
Categories: Cancer

Rare ribosomopathies: insights into mechanisms of cancer

Nature Rev. Cancer - 22 January 2019 - 12:00am

Rare ribosomopathies: insights into mechanisms of cancer

Rare ribosomopathies: insights into mechanisms of cancer, Published online: 22 January 2019; doi:10.1038/s41568-019-0105-0

Rare ribosomopathies: insights into mechanisms of cancer
Categories: Cancer

Publisher Correction: Expanding the search

Nature Rev. Cancer - 17 January 2019 - 12:00am

Publisher Correction: Expanding the search

Publisher Correction: Expanding the search, Published online: 17 January 2019; doi:10.1038/s41568-019-0107-y

Publisher Correction: Expanding the search
Categories: Cancer

Fasting in oncology: a word of caution

Nature Rev. Cancer - 16 January 2019 - 12:00am

Fasting in oncology: a word of caution

Fasting in oncology: a word of caution, Published online: 16 January 2019; doi:10.1038/s41568-018-0098-0

Fasting in oncology: a word of caution
Categories: Cancer

Reply to ‘Fasting in oncology: a word of caution’

Nature Rev. Cancer - 16 January 2019 - 12:00am

Reply to ‘Fasting in oncology: a word of caution’

Reply to ‘Fasting in oncology: a word of caution’, Published online: 16 January 2019; doi:10.1038/s41568-018-0100-x

Reply to ‘Fasting in oncology: a word of caution’
Categories: Cancer

Modelling cancer in microfluidic human organs-on-chips

Nature Rev. Cancer - 15 January 2019 - 12:00am

Modelling cancer in microfluidic human organs-on-chips

Modelling cancer in microfluidic human organs-on-chips, Published online: 15 January 2019; doi:10.1038/s41568-018-0104-6

In vitro cancer models often fail to faithfully recapitulate the local tissue and organ microenvironment. Organs-on-chips can overcome this limitation and better mimic in vivo cancer phenotypes. This Review outlines the advances that have been made with this technology and explains the challenges that must be overcome to see its implementation into drug development pipelines and clinical cancer care.
Categories: Cancer

Get to know your epigenetic target

Nature Rev. Cancer - 7 January 2019 - 12:00am

Get to know your epigenetic target

Get to know your epigenetic target, Published online: 07 January 2019; doi:10.1038/s41568-018-0103-7

Two studies suggest that caution is warranted in attempts to inhibit the histone methyltransferase G9a for cancer therapy, as its loss can promote tumour development and evolution.
Categories: Cancer

Pages